TNG 456
Alternative Names: TNG-456Latest Information Update: 12 Dec 2024
Price :
$50 *
At a glance
- Originator Tango Therapeutics
- Class Antineoplastics
- Mechanism of Action PRMT5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Glioblastoma; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 06 Nov 2024 Tango Therapeutics plans a phase I/II trial in Glioblastoma, Non-small cell lung cancer, Solid tumours (Monotherapy, Combination therapy) in the first half of 2025 (unspecified)
- 06 Nov 2024 Preclinical trials in Glioblastoma (Combination therapy) in USA (unspecified route) prior to November 2024
- 06 Nov 2024 Preclinical trials in Glioblastoma in USA (unspecified route) (Tango Therapeutics pipeline, November 2024)